Significance and Innovations:
 In patients with systemic vasculitis in remission there needs to be a balance of risk between the side-effects associated with immunosuppression and disease activity. This balance must be individualised to each patient but this is often difficult . Measurement of total IgG and B cell counts in patients with systemic vasculitis in remission helps identify those most at risk of infection.
 This study identifies that the humoral response to vaccination predicts those at greatest risk of all-cause mortality, with the commonest cause of death being infection.
 Vaccination in this group of patients is safe
 Humoral response to vaccination, total IgG level and B cell counts taken together may identify a subset of patients who are at greatest risk from the side-effects of immunosuppressive therapy.
Despite improved treatments, patients with systemic vasculitis continue to have increased all-cause mortality compared to healthy individuals. Specifically, patients with ANCA-associated vasculitis have a 2.6 mortality ratio compared with the healthy population, with infection being the most frequent cause of death [1] , and associated with prolonged use of immunosuppression. Infection is also an important cause of morbidity. In the first year following diagnosis, when immunosuppression is at its highest, 25% of patients with systemic vasculitis had an infection episode [2] . Although infection risk reduces with time in these patients, it remains elevated compared to the healthy population. The risk of admission to hospital with pneumonia, a vaccine preventable illness, in these patients is increased at up to 5 times that of an age matched healthy population [3] . Identification and prevention of those at high risk of side-effects associated with therapy is essential to improve outcomes in these patients.
Cumulative immunosuppression [4] , age and severity of renal impairment [2] , are important risk factors for infection and mortality. However no immune biomarkers, beyond leucopenia [5] , have been shown to help identify those with poor functional immune systems and increased risk of infection. Vaccination is not only therapeutic but also provides information on the health of the immune system. Vaccination is recommended for immunosuppressed patients to prevent infection; however the immune response is often poorer than in healthy controls [6] . Failure to mount an effective response to vaccination along with detailed investigation of the immune system may identify those patients most at risk of infection and death.
The aim of this study was to investigate whether detailed investigation of the immune system and the immune response to vaccination in patients with systemic vasculitis predicted all-casue mortality and risk of infection. Patients were eligible for vaccination if they had been in stable remission > 6 months (Birmingham Vasculitis Activity Score=0); had received cyclophosphamide and steroid induction therapy but not within 6 months; had not received rituximab within 6 months; were on ≤ 10mg prednisolone per day; currently treated with no more than one immunosuppressant in addition to prednisolone; had no active infection; were not pregnant and had no history of previous severe adverse reaction to vaccination or received vaccination with the proposed vaccines. Clinical and laboratory data were recorded from patient records. Infection episodes following vaccination were prospectively identified from patient notes. Severe infections were defined as requiring admission to hospital and/or intravenous antibiotic therapy. Patients requiring intravenous immunoglobulin (IVIg) were excluded from the study. Causes of death during follow up were determined from death certificate data.
METHODS
Patients had blood collected immediately pre-vaccination for lymphocyte subset analysis by flow cytometry (CD3, CD4, CD8, CD19, CD16, CD56; all Becton Antibody titres against Pn, HIb and Men were assayed by the CIL using a multiplex assay which is externally quality assured by United Kingdom National External Quality Assessment Service, Sheffield, UK [7] . Serum was separated from blood and frozen at -20°C until analyzed. There is inherent variability in functional antibody testing so to minimise inter-assay variability samples were batch analysed such that all samples from an individual patient were included in the same analysis.
For antibody titre threshold analysis Pn titres >0.35 ug/ml, Men titres >2 ug/ml and HIb >1 ug /ml were considered to be above threshold. It is unknown what a protective pneumococcal antibody titre is in adults and may vary according to serotype and published concentrations vary from 0.15 -2 ug /ml. A cut off of 0.35 ug /ml is recommended by World Health Organisation for infants and is used widely in the UK for adults.
Antibody response scores were calculated using the formula 100 *
We assessed response as the proportion of below "protective" threshold antibody titres that changed to above threshold titres following vaccination. Where 12 is the total number of antibody titres measured for each patient and T is time post vaccination. Patients with all 12 antibody titres >threshold, could not improve their response from pre-vaccination levels (n=5) and were excluded from this analysis.
Statistical analysis
Continuous data is presented as median (inter-quartile range) unless stated. 
RESULTS

Ninety two patients
Immune biomarkers predict infection
At the time of vaccination all patients had a total white cell count within the normal range with normal neutrophil and NK cell counts. The median total lymphocyte count was low, with low CD3 + T cells and CD19 + B cells (table 1) . Thirty seven percent of patients had CD4 + cell counts less than the lower limit of normal and 44% patients had CD8 + cell counts below the normal range. Twenty two percent of patients had low IgG levels. Serum IgG concentration correlated with B cell count (cc=0.33; p=0.002), and CD4 count (cc=0.3; p=0.005).
B cell count correlated negatively with previous cumulative cyclophosphamide exposure (cc=-0.29; p=0.012); CD4 count correlated negatively with age (cc=-0.35; p=0.001); both B cell count and CD4
T cell count correlated positively with eGFR (cc=0.25; p=0.022 and cc=0.35; p=0.001 respectively).
Overall infection rates correlated negatively with serum IgG (r= -0.27; p=0.01), CD4 cell count (r=- Patients on maintenance immunosuppression at the time of vaccination had lower B cell counts, CD4
T cell counts and serum IgG concentrations but higher eGFR than patients on steroids only or no maintenance therapy (figure 2), suggesting a more dysfunctional immune system. There was no difference in CD8 + counts between those still on maintenance immunosuppression and those who had discontinued it.
Patients on maintenance immunosuppression had more infections per year during follow up (0 (0-0.2) vs 0. 6 (0.2-1.5); p=0.0001) although there was no difference in the serious infection rate between patients on maintenance immunosuppression and those who had discontinued immunsuppression (0 (0-0.2) vs 0 (0-0.2); p=0.7). Previous cumulative steroid dose correlated with the overall infection rate (r=0.21; p=0.043) but not the serious infection rate (r=0.18; p=0.097).
There was no difference between patients still on immunosuppression and those who had discontinued with regards to age and previous cyclophosphamide or steroid use. There was no relationship between previous cumulative cyclophosphamide use and the infection or serious infection rate. There was no correlation between age and all infections but there was a nonsignificant correlation between age and the serious infection rate (r=0.2; p=0.056).
Vaccine Response
The median antibody titres for all the vaccine components increased at 4 weeks post vaccination Only 9 of our patients had received rituximab and all at least 6 months prior to vaccination. It is well known that rituximab reduces the efficacy of vaccination, especially if given within the first few months post rituximab treatment [9] . This study suggests that B cell depletion due to other causes, such as cyclophosphamide, also influence the efficacy of vaccination, along with low IgG levels and CD4+ cell counts. We have also identified effects of anti-proliferative immunosuppressants on vaccine responses. This differs to previous GPA patients vaccinated with influenza, which showed no effect of immunosuppressive therapy [10] . The effect seen in our study may be due to differences in vaccines used and the larger cohort size in our study.
The response of patients to individual antigens was poor with fewer than 50% of patients responding to most antigens. A poor response to the vaccination was indicative of poor immunological function with low IgG, B cell counts and CD4+ T cell counts predicting vaccine response score. Those patients with a poor vaccine response were more likely to be on maintenance immunosuppression. This study extends previous findings that identified low CD4+ T cell counts as a risk for lack of humoral immunity to tetanus [11] . B cell counts have been identified as predictive of a memory response to vaccination in children with HIV [12] . Although other studies have shown reduced response to vaccination in immunosuppressed populations, this is the first study to assess immunological predictors of vaccine response in an adult population with systemic vacsulitis on immunosuppressive therapy.
Previously there has been concern regarding the risk of vaccination triggering a relapse of vasculitis.
We found no increase in the risk of relapse following vaccination. Similar findings have been reported in previous studies of influenza vaccination in AAV patients [10, [13] [14] [15] .
We used conjugate pneumococcal vaccine in this study, as a rapid decrease in antibody levels to the polysaccharide vaccine, pneumovax, has been reported in elderly and immunocompromised patients [16] [17] [18] . In our study patients able to mount an effective immune response maintained "protective" antibody responses up to 2 years, suggesting that vaccination remains an important preventative measure against infection. However absolute titres of antibody did decline over the period of follow up. Similar results were found in patients with inflammatory arthritis who showed a reduction in antibody titres over 18 months [19] . Both these studies suggest that in patients who are immunocompromised early revaccination strategies may be required.
Although vaccination response did not predict infection, those cellular and humoral biomarkers predicting poor vaccine response did predict infection in patients with systemic vasculitis in stable remission. Low serum IgG, B cell counts, cumulative steroid exposure and maintenance therapy were identified as important risk factors for any infection, but not all-cause mortality, while reduced renal function and CD4+ T cell counts additionally increased the risk for severe infection. This study suggests the vaccination score provides useful information on the health of the immune system and provides a surrogate marker of poor immune response, which may identify those patients potentially benefitting from a reduction in immunosuppression. For those who require long-term immunosuppression due to continued disease activity, this data may help identify those patients who require additional intervention to reduce risk of infection.
This study confirmed previous associations between infection and impaired renal function, corticosteroid exposure and lymphopenia [20, 21] [22]. We extended these observations by demonstrating that CD4 cell counts were associated with severe infection and reduced B cells and low serum IgG was associated with an increased risk of all infections. Our study differs from previous reports [4, 20, 23] , in that we did not find a direct association between previous cyclophosphamide use and infection. This may reflect the reduced cumulative dose when using pulsed cyclophosphamide regimens, which is associated with fewer episodes of leucopoenia compared with daily oral cyclophosphamide [24] . We did, however, show a correlation between cyclophosphamide exposure and B cell count suggesting that, even in an era of reduced cyclophosphamide use the long term impact on the immune system may be important.
In our study patients at risk of all-cause mortality as predicted by a poor vaccination response have a combined deficiency in both the cellular and humoral parts of the immune system. Severe infection rates were similar to that seen in primary immunodeficiencies, such as combined variable immunodeficiency syndrome (CVID). Immune deficiencies in patients with CVID are characterised by a reduced serum IgG, and reduced subsets of B cells and T cells in the peripheral blood [25] . There is an increased risk of susceptibility to respiratory infection with encapsulated bacteria [26] . Patients with CVID treated with IVIg reconstitution have reduced infection and improved cellular immunity [27] . The commonest infection described in patients with systemic vasculitis is respiratory tract infection [3] . IVIg replacement may be beneficial for patients with systemic vasculitis and recurrent infection, who have low IgG levels, reduced CD4+ and CD19+ lymphocytes and respond poorly to vaccination.
Several limitations of this study require comment. Information on the duration of pneumocystis jiroveci prophylaxis was not available in sufficient detail to allow comment on its ability to reduce bacterial infection in this cohort. Although vaccination aims to reduce infection, due to the large sample size required for such a study and the difficulty in proving bacterial diagnosis this study was not powered to investigate changes in infection rates in response to vaccination. Good data exists for predictors of infection and mortality and vaccine responses are known to be lower during times of intense immunosuppression. We, therefore, focussed on patients who were in sustained remission and had not received induction therapy within the last 6 months and followed them prospectively, as little has previously been known about risk factors for infection or all-casue mortality in this group. Infection rates in this study are lower than previously reported and reflect the reduced immunosuppression used in patients in stable remission and may explain the lack of association between vaccination response and infection. We included meningitis vaccination in this study, although not standard vaccination for this group, it allowed us to assess both T cell dependent and T independent vaccines. As expected response to the polysaccharide vaccinations were lower than to the conjugate vaccines but all patients did respond to a degree. Although this may limit the applicability of the vaccine response score, it provided important information on the response to polysaccharide vaccines.
In conclusion, this study identifies older patients with poor renal function and vaccine responses to No financial support was received for this work. 
